PTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($0.86), $0.11 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.71 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.